Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Orasis Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CSF-1

            Therapeutic Area: Ophthalmology Product Name: PresbiDrops

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bluestem Capital

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing September 10, 2020

            Details:

            Proceeds from the financing will be used to advance Orasis’ lead eye drop candidate for the treatment of presbyopia symptoms through completion of its Phase 3 clinical trials.